|
1
|
Heitzer E, Haque IS, Roberts CES and
Speicher MR: Current and future perspectives of liquid biopsies in
Genomics-driven oncology. Nat Rev Genet. 20:71–88. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tivey A, Church M, Rothwell D, Dive C and
Cook N: Circulating tumour DNA-looking beyond the blood. Nat Rev
Clin Oncol. 19:600–612. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kotani D, Oki E, Nakamura Y, Yukami H,
Mishima S, Bando H, Shirasu H, Yamazaki K, Watanabe J, Kotaka M, et
al: Molecular residual disease and efficacy of adjuvant
chemotherapy in patients with colorectal cancer. Nat Med.
29:127–134. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ignatiadis M, Sledge GW and Jeffrey SS:
Liquid biopsy enters the clinic-implementation issues and future
challenges. Nat Rev Clin Oncol. 18:297–312. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cristofanilli M, Hayes DF, Budd GT, Ellis
MJ, Stopeck A, Reuben JM, Doyle GV, Matera J, Allard WJ, Miller MC,
et al: Circulating tumor cells: A novel prognostic factor for newly
diagnosed metastatic breast cancer. J Clin Oncol. 23:1420–1430.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cristofanilli M: Circulating tumor cells,
disease progression, and survival in metastatic breast cancer.
Semin Oncol. 33 (Suppl 9):S9–S14. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chae YK, Davis AA, Jain S, Santa-Maria C,
Flaum L, Beaubier N, Platanias LC, Gradishar W, Giles FJ and
Cristofanilli M: Concordance of genomic alterations by
Next-generation sequencing in tumor tissue versus circulating tumor
DNA in breast cancer. Mol Cancer Ther. 16:1412–1420. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dagogo-Jack I and Shaw AT: Tumour
heterogeneity and resistance to cancer therapies. Nat Rev Clin
Oncol. 15:81–94. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ma F, Guan Y, Yi Z, Chang L, Li Q, Chen S,
Zhu W, Guan X, Li C, Qian H, et al: Assessing tumor heterogeneity
using ctDNA to predict and monitor therapeutic response in
metastatic breast cancer. Int J Cancer. 146:1359–1368. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Siravegna G, Mussolin B, Buscarino M,
Corti G, Cassingena A, Crisafulli G, Ponzetti A, Cremolini C, Amatu
A, Lauricella C, et al: Clonal evolution and resistance to EGFR
blockade in the blood of colorectal cancer patients. Nat Med.
21:8272015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Murtaza M, Dawson SJ, Pogrebniak K, Rueda
OM, Provenzano E, Grant J, Chin SF, Tsui DWY, Marass F, Gale D, et
al: Multifocal clonal evolution characterized using circulating
tumour DNA in a case of metastatic breast cancer. Nat Commun.
6:87602015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Rothé F, Laes JF, Lambrechts D, Smeets D,
Vincent D, Maetens M, Fumagalli D, Michiels S, Drisis S, Moerman C,
et al: Plasma circulating tumor DNA as an alternative to metastatic
biopsies for mutational analysis in breast cancer. Ann Oncol.
25:1959–1965. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Diaz LA Jr and Bardelli A: Liquid
biopsies: Genotyping circulating tumor DNA. J Clin Oncol.
32:579–586. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Murtaza M, Dawson SJ, Tsui DWY, Gale D,
Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS,
et al: Non-invasive analysis of acquired resistance to cancer
therapy by sequencing of plasma DNA. Nature. 497:108–112. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Low SKK, Uchibori K, Hayashi R, Chan T,
Ariyasu R, Kitazono S, Yanagitani N, Nishio M and Nishio Y:
Evaluation of Genexus system that automates specimen-to-report for
cancer genomic profiling within a day using liquid biopsy. J Clin
Orthod. 38 (Suppl 15):S3538. 2020.
|
|
16
|
Casuga I, Chan F, Huynh M, Govoni GR,
Zochowski K, Jayaweera J and Au-Young J: Abstract 2944: Rapid and
accurate variant calling of FFPE samples with the Genexus System.
Cancer Res. 82:2944. 2022. View Article : Google Scholar
|
|
17
|
Guo F, Lang Y, Long G, Liu Z, Jing G, Zhou
Y, Zhang B and Yu S: Ion Torrent TM Genexus
TM Integrated Sequencer and ForeNGS Analysis Software-An
automatic NGS-STR workflow from DNA to profile for forensic
science. Forensic Sci Int Genet. 61:1027532022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mok T, Wu YL, Lee JS, Yu CJ, Sriuranpong
V, Sandoval-Tan J, Ladrera G, Thongprasert S, Srimuninnimit V, Liao
M, et al: Detection and dynamic changes of EGFR mutations from
circulating tumor DNA as a predictor of survival outcomes in NSCLC
patients treated with First-line intercalated erlotinib and
chemotherapy. Clin Cancer Res. 21:3196–3203. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zill OA, Greene C, Sebisanovic D, Siew LM,
Leng J, Vu M, Hendifar AE, Wang Z, Atreya CE, Kelley RK, et al:
Cell-Free DNA Next-generation sequencing in pancreatobiliary
carcinomas. Cancer Discov. 5:1040–1048. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim ST, Lee WS, Lanman RB, Mortimer S,
Zill OA, Kim KM, Jang KT, Kim SH, Park SH, Park JO, et al:
Prospective blinded study of somatic mutation detection in
cell-free DNA utilizing a targeted 54-gene next generation
sequencing panel in metastatic solid tumor patients. Oncotarget.
6:40360–40369. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Janku F, Angenendt P, Tsimberidou AM, Fu
S, Naing A, Falchook GS, Hong DS, Holley VR, Cabrilo G, Wheler JJ,
et al: Actionable mutations in plasma cell-free DNA in patients
with advanced cancers referred for experimental targeted therapies.
Oncotarget. 6:12809–12821. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Morimoto Y, Matsuda S, Kawakubo H,
Nakamura K, Kobayashi R, Hisaoka K, Okui J, Takeuchi M, Aimono E,
Fukuda K, et al: ASO visual abstract: Tumor burden monitoring with
circulating tumor DNA during treatment in patients with esophageal
squamous cell carcinoma. Ann Surg Oncol. 30:37592023. View Article : Google Scholar
|
|
23
|
Morimoto Y, Matsuda S, Kawakubo H,
Nakamura K, Kobayashi R, Hisaoka K, Okui J, Takeuchi M, Aimono E,
Fukuda K, et al: Tumor burden monitoring with circulating tumor DNA
during treatment in patients with esophageal squamous cell
carcinoma. Ann Surg Oncol. 30:3747–3756. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kuderer NM, Burton KA, Blau S, Rose AL,
Parker S, Lyman GH and Blau CA: Comparison of 2 commercially
available Next-generation sequencing platforms in oncology. JAMA
Oncol. 3:996–998. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Barata PC, Koshkin VS, Funchain P, Sohal
D, Pritchard A, Klek S, Adamowicz T, Gopalakrishnan D, Garcia J,
Rini B and Grivas P: Next-generation sequencing (NGS) of cell-free
circulating tumor DNA and tumor tissue in patients with advanced
urothelial cancer: A pilot assessment of concordance. Ann Oncol.
28:2458–2463. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Jahangiri L and Hurst T: Assessing the
concordance of genomic alterations between circulating-free DNA and
tumour tissue in cancer patients. Cancers (Basel). 11:19382019.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Thompson JC, Yee SS, Troxel AB, Savitch
SL, Fan R, Balli D, Lieberman DB, Morrissette JD, Evans TL, Bauml
J, et al: Detection of therapeutically targetable driver and
resistance mutations in lung cancer patients by next-generation
sequencing of Cell-free circulating tumor DNA. Clin Cancer Res.
22:5772–5782. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Schwaederlé MC, Patel SP, Husain H, Ikeda
M, Lanman RB, Banks KC, Talasaz A, Bazhenova L and Kurzrock R:
Utility of genomic assessment of blood-derived circulating tumor
DNA (ctDNA) in patients with advanced lung adenocarcinoma. Clin
Cancer Res. 23:5101–5111. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Guo Q, Wang J, Xiao J, Wang L, Hu X, Yu W,
Song G, Lou J and Chen J: Heterogeneous mutation pattern in tumor
tissue and circulating tumor DNA warrants parallel NGS panel
testing. Mol Cancer. 17:1312018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Bettegowda C, Sausen M, Leary RJ, Kinde I,
Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, et al:
Detection of circulating tumor DNA in early- and Late-stage human
malignancies. Sci Transl Med. 6:224ra242014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Aran D, Sirota M and Butte AJ: Systematic
pan-cancer analysis of tumour purity. Nat Commun. 6:89712015.
View Article : Google Scholar : PubMed/NCBI
|
